A recently published systematic review and meta-analysis evaluated the comparative effectiveness of bariatric surgery and GLP-1 receptor agonists in adults with obesity.
The study, which included over 20,000 patients across 15 studies, provides important insight into how these two widely used treatment approaches perform over time.
As obesity continues to be recognized as a chronic, multifactorial disease, understanding the long-term outcomes of available treatments is essential for informed decision-making.
Study Overview
The analysis reviewed data from major databases including MEDLINE, EMBASE, and CENTRAL through October 2025. Outcomes assessed included:
- Weight loss
- Body Mass Index (BMI) reduction
- Glycemic control (HbA1c, fasting glucose)
- Lipid profile
- Blood pressure
A random-effects model was used to evaluate pooled outcomes across different timeframes.
Key Findings
One of the most relevant conclusions of the study is:
“Bariatric surgery was associated with greater and sustained reductions observed over multi-year follow-up in weight, BMI, and glycaemic indices compared to GLP-1 receptor agonists.”
Weight Loss Outcomes
- At 6 months, no statistically significant difference was observed
- At ≤ 1 year, bariatric surgery showed significantly greater weight loss
- At > 1 year, the difference further increased in favor of surgery
BMI Reduction
Bariatric surgery demonstrated consistently greater reductions in BMI across all time points evaluated.
Glycemic Control
- Greater HbA1c reduction with bariatric surgery beyond one year
- Lower fasting glucose levels overall in surgical patients
Other Cardiometabolic Outcomes
- No significant differences were observed in:
- Lipid profile
- Blood pressure
Comparative Outcomes
| Outcome | GLP-1 Medications | Bariatric Surgery |
| Short-term weight loss | Comparable at 6 months | Comparable at 6 months |
| Long-term weight loss | Moderate, variable | Greater and sustained |
| BMI reduction | Moderate | Greater at all time points |
| HbA1c reduction | Effective | Greater beyond 1 year |
| Fasting glucose | Improved | Lower overall |
| Lipid profile | No major difference | No major difference |
| Blood pressure | No major difference | No major difference |
Clinical Interpretation
The findings highlight an important distinction between these treatment modalities:
- GLP-1 receptor agonists can support weight loss and metabolic improvements, particularly in the short term
- Bariatric surgery demonstrates greater magnitude and durability of outcomes, especially beyond the first year
The study also noted variability based on patient characteristics, with larger BMI reductions observed in:
- Older patients
- Male patients
- Individuals with higher baseline BMI
These findings reinforce the importance of individualized treatment planning, considering both short-term goals and long-term disease management.
What This Means for Patients
- The chronic nature of obesity
- The need for long-term strategies
- The importance of selecting the right treatment for the right patient
Understanding how different therapies perform over time allows patients to make more informed decisions in collaboration with their medical team.
As more high-quality studies emerge, a consistent pattern is observed:
Bariatric surgery is associated with greater and more sustained outcomes in weight loss, BMI reduction, and glycemic control, particularly over long-term follow-up.
At the same time, pharmacologic therapies continue to play a role in the broader management of obesity.
As more high-quality studies emerge, a consistent pattern is observed:
Bariatric surgery is associated with greater and more sustained outcomes in weight loss, BMI reduction, and glycemic control, particularly over long-term follow-up.
At the same time, pharmacologic therapies continue to play a role in the broader management of obesity.
